Progyny (PGNY) Projected to Post Earnings on Wednesday

Progyny (NASDAQ:PGNY) is anticipated to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.3130 per share and revenue of $340.76 million for the quarter. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The company had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. During the same quarter in the previous year, the company earned $0.19 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts expect Progyny to post $1.25 EPS for the current fiscal year and $1.42 EPS for the next fiscal year.

Progyny Price Performance

PGNY stock traded down $0.12 during trading on Tuesday, hitting $29.29. The stock had a trading volume of 30,957 shares, compared to its average volume of 1,354,468. Progyny has a twelve month low of $16.10 and a twelve month high of $33.06. The company’s 50-day moving average price is $26.95 and its two-hundred day moving average price is $24.45. The stock has a market capitalization of $2.25 billion, a P/E ratio of 31.78, a PEG ratio of 1.92 and a beta of 1.02.

Insider Transactions at Progyny

In other news, EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the transaction, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. The trade was a 4.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa Cummings sold 1,879 shares of Progyny stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total transaction of $52,612.00. Following the completion of the transaction, the chief operating officer owned 66,496 shares in the company, valued at approximately $1,861,888. This represents a 2.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 17,282 shares of company stock worth $475,790. Insiders own 9.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Leerink Partners set a $38.00 price objective on Progyny in a research report on Wednesday, July 22nd. Wall Street Zen downgraded Progyny from a “strong-buy” rating to a “buy” rating in a research report on Saturday. KeyCorp raised their price objective on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Truist Financial lifted their price objective on shares of Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Finally, Citigroup reiterated an “outperform” rating on shares of Progyny in a research note on Tuesday, September 8th. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.36.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.